Table 5.

Reclassification based on fibroblast growth factor 23 levels

Without FGF23With FGF23 (n)Total (n)
<5%5%–10%>10%
Estimated risk of cardiovascular mortalitya
 Patients with cardiovascular mortality
  <5%21b3
  5%–10%66
  >10%2c5557
  Total295566
 Patients without cardiovascular mortality
  <5%18612c1c199
  5%–10%46b7515c136
  >10%27b15178
  Total232114167513
Estimated risk of all-cause mortalityd
 Patients with all-cause mortality
  <5%11b1b3
  5%–10%3c32b8
  >10%3c114117
  Total47117128
 Patients without all-cause mortality
 <5%926c98
 5%–10%24b419c74
 >10%5b44b230279
 Total12191239451
  • Multivariate model adjusted for Framingham risk factors (recipient age and sex, systolic BP, antihypertensive treatment use, smoking status, diabetes mellitus, plasma total cholesterol and HDL cholesterol) with or without plasma C-terminal fibroblast growth factor 23 level. FGF23, fibroblast growth factor 23.

  • a Net reclassification improvement was 0.07 (95% confidence interval [CI], 0.01 to 0.14; P<0.05).

  • b Numbers of patients who were correctly reclassified by the model with FGF23.

  • c Numbers of patients who were incorrectly reclassified by the model with FGF23.

  • d Net reclassification improvement was 0.11 (95% CI, 0.05 to 0.18; P<0.001).